Discover how the FDA’s new regulatory framework for psychedelic clinical trials is setting rigorous safety and efficacy standards for psychiatric care.
The FDA has approved apitegromab, the first myostatin inhibitor for SMA, offering a new way to treat muscle atrophy alongside standard genetic therapies.
Biopharma leader DYN is accelerating toward a dual-drug commercial launch backed by strong clinical data, expanded research, and a solid financial runway.
The FDA is seeking public feedback on regulating GenAI in medical devices. Learn about the new efforts to manage safety, bias, and innovation in AI healthcare.
Spectral Medical meets with the FDA to discuss the PMX device PMA application for treating septic shock. Get the latest update on this critical review.